Seagen label for Tukysa in CRC broader-than-expected, says William Blair

After Seagen announced the accelerated approval of Tukysa in combination with Herceptin in second-line and later unresectable or metastatic colorectal cancer, or mCRC, William Blair analyst Andy Hsieh noted that the label allows the possibility of treating patients as early as second-line and called it "broader-than-expected." While the commercial opportunity for this approval is "modest," he believes the expansion into HER2-positive indications beyond breast cancer is "a worthwhile endeavor" and represents a "modest growth opportunity." Hsieh reiterates an Outperform rating on Seagen shares.